NewsResearch
CheckMate 649: What the Stomach Cancer Trial Found
CheckMate 649 tested nivolumab + chemo vs chemo in stomach cancer, measuring overall survival. Plain-language summary of a result widely described as practice-influencing — and what it doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
The problem the trial was set against
Before this trial, first-line chemotherapy for advanced HER2-negative stomach or gastro-esophageal junction adenocarcinoma gave a median overall survival of under a year. That fact opens the published report. It also explains why the trial existed.
CheckMate 649 asked whether adding an immunotherapy drug to that chemotherapy would help.
What the trial did
ClinicalTrials.gov records NCT02872116 as a phase 3 study that opened on 12 October 2016 and reached primary completion on 27 May 2020, with 2,031 participants across all its arms.
The published comparison covered 1,581 people, randomized at the same time. They came from 175 hospitals in 29 countries, between March 2017 and April 2019. In all, 2,687 people were assessed for eligibility. The 1,581 who joined were split evenly. Seven hundred and eighty-nine got nivolumab plus chemotherapy. Seven hundred and ninety-two got chemotherapy alone.
Everyone had untreated adenocarcinoma of the stomach, the gastro-esophageal junction, or the esophagus. None of the tumors could be removed by surgery, and none was HER2-positive. One point matters: people joined whatever the level of PD-L1 in their tumor.
The chemotherapy was capecitabine with oxaliplatin every three weeks. Or it was leucovorin, fluorouracil and oxaliplatin every two weeks. Our page on what standard of care means in a trial explains why that choice matters so much.
What PD-L1 and CPS mean here
Nivolumab blocks PD-1, a switch on T cells that tumors use to shut down an immune attack. Blocking it can release the brake.
Whether it works depends partly on how much of the matching protein, PD-L1, is on show. Pathologists grade that with a combined positive score, or CPS. In rough terms, it is the number of PD-L1-stained cells divided by the number of tumor cells, times 100.
The trial set its main endpoints in advance, for people with a CPS of five or more. That choice was made before anyone saw the results. It is what makes the finding solid rather than a hunt through the data afterward.
The results
In the group with a CPS of five or more, adding nivolumab improved overall survival. The hazard ratio was 0.71. For progression-free survival it was 0.68. Both results were highly statistically significant. Minimum follow-up was 12.1 months.
Median follow-up for overall survival was 13.1 months in the nivolumab group and 11.1 months in the chemotherapy group.
The published report also describes significant survival improvement in the wider randomized population, not only in the high-PD-L1 group.
What FDA did with it
The current prescribing information for nivolumab names a specific group. It covers adults with advanced or metastatic gastric cancer, gastro-esophageal junction cancer, and esophageal adenocarcinoma. Their tumors must express PD-L1 at a score of one or more. And the drug is given with fluoropyrimidine- and platinum-containing chemotherapy.
Note the threshold in the label. The trial took everyone, whatever their PD-L1 level. Its main analysis used a score of five or more. The approved indication names a score of one or more. Trial design, published analysis and label wording are three different documents. They do not always use the same cut-off.
The disease behind the trial
Stomach cancer is usually found late. NCI reports that early-stage disease accounts for only 10% to 20% of cases diagnosed in the United States, because early symptoms look like indigestion.
About 31,510 new stomach cancer diagnoses and about 10,740 deaths are projected in the United States for 2026. That projection is the American Cancer Society's, carried on the SEER site. Median age at diagnosis is 68.
Thirty-five percent of cases are found after distant spread, where five-year relative survival is 8.1%. Across all stages it is 39.8% for people diagnosed from 2016 through 2022. Our overview of stomach cancer covers the disease in more detail.
Those are group averages from a registry and not a prediction for anyone.
What this does not mean
- A hazard ratio of 0.71 is a rate of events over time, not a percentage of people helped. It does not mean 29% of people benefited.
- The headline result belongs to the group with a PD-L1 score of five or more. Reading it as a result for everyone with stomach cancer overstates what was measured.
- Median follow-up was around a year. Long-term outcomes were not established by this report.
- Adding a drug adds side effects. Immune checkpoint inhibitors can set off inflammation in the lung, bowel, liver, skin and hormone glands. The trial checked safety in everyone who got at least one dose.
- This describes a trial, not a treatment plan. Our page on questions to ask about a clinical trial covers how to raise it with a team.
Sources
- NCBI eutils: Janjigian et al., Lancet 2021;398:27-40 (CheckMate 649, PMID 34102137)
- ClinicalTrials.gov API v2: NCT02872116 (CheckMate 649)
- openFDA drug label API: OPDIVO (nivolumab)
- NCI: Stomach (Gastric) Cancer—Patient Version
- NCI SEER Stat Facts: Stomach Cancer
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Stomach cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.